Synonyms: compound 3 [PMID: 29960205] | Fetcroja® | Fetroja® | GSK-2696266 | GSK2696266 | RSC 649266 | RSC-649266 | RSC649266 | S-649266
cefiderocol is an approved drug (FDA (2019), EMA (2020))
Compound class:
Synthetic organic
Comment: Cefiderocol (S-649266) is a novel parenteral cephalosporin antibacterial with Gram-negative activity including against multi-drug resistant bacteria [1,3]. Chemically it is a catechol-conjugated siderophore cephalosporin. It was developed to treat bloodstream infections, hospital-acquired and ventilator-associated bacterial pneumonia, and complicated urinary tract infections. It can be formulated as the sulphate tosylate complex. Cefiderocol was the first siderophore class antibacterial to be approved by FDA.
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (FDA (2019), EMA (2020)) |
WHO Essential Medicine | WHO Essential Medicines List (EML) (23rd List, 2023). Access PDF version. Click to view more information about the WHO Model Lists of Essential Medicines. |
International Nonproprietary Names | |
INN number | INN |
10234 | cefiderocol |
Synonyms |
compound 3 [PMID: 29960205] | Fetcroja® | Fetroja® | GSK-2696266 | GSK2696266 | RSC 649266 | RSC-649266 | RSC649266 | S-649266 |
Database Links | |
Specialist databases | |
Antibiotic DB | Cefiderocol (S-649266; GSK-2696266; RSC 649266) |
Other databases | |
CAS Registry No. | 1225208-94-5 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL3989974 |
DrugCentral Ligand | 5352 |
GtoPdb PubChem SID | 405560217 |
PubChem CID | 77843966 |
Search Google for chemical match using the InChIKey | DBPPRLRVDVJOCL-FQRUVTKNSA-N |
Search Google for chemicals with the same backbone | DBPPRLRVDVJOCL |
Search PubMed clinical trials | cefiderocol |
Search PubMed titles | cefiderocol |
Search PubMed titles/abstracts | cefiderocol |
UniChem Compound Search for chemical match using the InChIKey | DBPPRLRVDVJOCL-FQRUVTKNSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | DBPPRLRVDVJOCL-FQRUVTKNSA-N |